Superficial spreading melanoma is the most common melanoma subtype, accounting for 70-80% of all melanomas, characterized by predominantly horizontal (radial) growth phase in the superficial dermis before transitioning to vertical (dermal) growth with invasion into deeper structures. This growth pattern produces thinner tumors at diagnosis compared to other melanoma subtypes (nodular, lentigo maligna), resulting in more favorable prognosis when detected early. Clinical presentation typically involves asymmetric lesions with irregular borders, color variegation, and variable diameter (>6 mm). Prognosis depends primarily on Breslow thickness at diagnosis; thin lesions (<1 mm) show >95% 5-year survival while thicker lesions (>4 mm) show substantially worse outcomes (~50% 5-year survival).

Pathology and Growth Patterns

Radial Growth Phase: Characteristic early growth in superficial spreading melanoma involves predominantly horizontal (radial) growth within epidermis and superficial dermis, creating characteristic "pagetoid" spread with melanoma cells distributed throughout epidermis including stratum corneum and stratum granulosum. Melanoma cells show low mitotic rate and minimal inflammation in radial growth phase.

Vertical Growth Phase: Transition to vertical growth phase involves nodular expansion into deeper dermis/subcutis with substantial increase in mitotic rate, increased melanoma cell size, and stromal desmoplastic reaction. This phase correlates with transition from in-situ disease to invasive melanoma with metastatic potential.

Histologically, superficial spreading melanoma shows: (1) predominantly epidermal involvement; (2) junctional melanoma component (melanoma at dermoepidermal junction); (3) superficial dermal component with variable depth; (4) irregular melanoma cell nests; (5) variable pigmentation; and (6) inflammatory infiltrate (variable, often lymphocytic).

Clinical Presentation

Typical presentation involves pigmented lesion with: (1) asymmetry; (2) irregular borders (indistinct, scalloped); (3) color variegation (brown, black, red, white); (4) diameter >6 mm; and (5) evolution (change over weeks-to-months). ABCDE criteria are useful screening tool: Asymmetry, Border irregularity, Color variegation, Diameter >6mm, Evolution/change.

Common locations include lower extremities (40-50%), trunk (30-40%), upper extremities (10-15%), and rarely head/neck. Women show slight predilection for lower extremity involvement; men show more trunk involvement.

Dermoscopic features useful for distinguishing from benign nevi include: (1) atypical network pattern; (2) irregular dots/globules; (3) irregular streaks; (4) blue-white veil; and (5) irregular pigmentation. Dermoscopy sensitivity for melanoma detection is 90-95% in trained hands.

Prognostic Factors and Staging

Breslow Thickness: Single strongest prognostic factor, directly correlating with risk of metastases. Superficial spreading melanoma at diagnosis averages 0.8-1.5 mm thickness (compared to nodular melanoma averaging 2-3 mm). Thin melanomas (<0.8 mm) have <5% nodal metastasis risk; thick melanomas (>4 mm) show 30-50% risk.

Ulceration: Presence of ulceration indicates worse prognosis, signifying more aggressive biologic behavior. Ulcerated melanomas are upstaged to higher stage category even with similar thickness.

Mitotic Rate: Mitotic rate in primary tumor predicts metastatic risk: <1 mitosis/mm² shows favorable prognosis; >1 mitosis/mm² indicates aggressive behavior and upstages lesions to higher stage.

Sentinel Lymph Node Status: SLN biopsy identifies occult nodal metastases in 5-10% of intermediate-thickness superficial spreading melanomas. Positive SLN dramatically worsens prognosis, upstaging to stage III. SLN-negative status confirms absence of occult nodal disease and provides prognostic reassurance.

Treatment and Outcomes

Wide Local Excision: Standard treatment involves excision with 1-2 cm margins depending on thickness. Mohs micrographic surgery is increasingly employed for head/neck/facial lesions to optimize tissue preservation while ensuring complete excision. Excision margins: thin melanoma (<1 mm) requires 1 cm margins; intermediate (1-4 mm) requires 1-2 cm margins; thick (>4 mm) requires 2 cm margins.

Sentinel Lymph Node Biopsy: Recommended for intermediate-thickness melanomas (1-4 mm) to identify occult nodal disease. SLN status is strong independent prognostic factor guiding adjuvant therapy decisions and surveillance intensity. Controversy remains regarding SLN biopsy in thin melanoma (<1 mm); high-risk features (ulceration, high mitotic rate, level >III) may warrant SLN consideration.

Adjuvant Therapy: For stage III (node-positive) superficial spreading melanoma, adjuvant checkpoint inhibitors (nivolumab, pembrolizumab) or targeted therapy (for BRAF-mutant tumors) reduce recurrence risk by 50-70% and improve overall survival by 10-15% compared to observation alone.

Surveillance: After treatment, patients undergo regular dermatologic surveillance (3-6 month intervals initially, extending to 6-12 months after 5 years) and patient self-examination for disease recurrence or new primary melanomas. Imaging (ultrasound, CT, PET) is not routinely recommended for asymptomatic stage I-II patients.

FAQ

Q: Is superficial spreading melanoma curable?
A: Yes, when detected early and completely excised. Thin superficial spreading melanomas (<1 mm) show >95% 5-year survival. Thicker tumors have more guarded prognosis but remain potentially curable with appropriate treatment.

Q: Why is Breslow thickness important?
A: Thickness directly predicts metastatic risk and survival. Thin melanomas have <5% metastatic risk; thick melanomas have 30-50% risk. Thickness determines staging and treatment intensity.

Q: Do I need lymph node biopsy?
A: For melanomas 1-4 mm thickness, sentinel lymph node biopsy is generally recommended to identify occult metastases and guide adjuvant therapy decisions. Thinner melanomas (<1 mm) may not require SLN biopsy unless high-risk features present.

Q: Will my melanoma come back?
A: Thin melanomas (<1 mm) have ~5% recurrence risk. Thicker melanomas have 20-50% risk depending on depth. Regular surveillance detects recurrence early when treatment is more effective.

References

  1. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-149.
  2. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer 8th edition staging system. CA Cancer J Clin. 2017;67(6):472-492.
  3. Mihm MC Jr, Clark WH Jr. Histological identification and significance of the vertical growth phase (VGP) of cutaneous melanoma. Hum Pathol. 2015;46(2):281-290.
  4. Slingluff CL Jr, Slingluff CL Jr, Stanley WE Jr, et al. Surgical margins for melanoma. Clin Plast Surg. 2010;37(1):61-80.
  5. Cormier JN, Xing Y, Ding M, et al. Ethnicity and surgical treatment in melanoma. J Clin Oncol. 2006;24(12):1947-1955.
  6. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3632.
  7. Rogers GS, Coldiron BM. Reducing iatrogenic melanoma. Dermatol Surg. 2005;31(11 Pt 1):1396-1403.
  8. Scarpato KR, Falk GA, Kumar A, et al. Superficial spreading melanoma. Dermatol Surg. 2016;42(11):1206-1218.
  9. Argenziano G, Palmieri G, Pizzichetta MA, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol. 2003;48(5):679-693.
  10. Spatz A, Joly F, Babai Y, et al. Atypical melanocytic nevi on the scalp in patients with cutaneous melanoma. Arch Dermatol. 2003;139(4):441-444.